ASCENSION ST JOHN HOSPITAL
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230165
- Received
- $1,066,958 in 225 records, 2023 ($30,000 general, $1,036,958 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 8 | $30,000 |
| 2023 | Research payment | 217 | $1,036,958 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 72 | $742,560 | 2023 |
| Medtronic, Inc. | 61 | $94,262 | 2023 |
| Genentech, Inc. | 17 | $44,118 | 2023 |
| Eli Lilly and Company | 3 | $38,386 | 2023 |
| Saranas, Inc. | 22 | $31,461 | 2023 |
| Penumbra, Inc. | 14 | $25,882 | 2023 |
| InspireMD Ltd | 1 | $16,716 | 2023 |
| Amgen Inc. | 1 | $14,000 | 2023 |
| AngioDynamics, Inc. | 1 | $13,000 | 2023 |
| Gilead Sciences, Inc. | 8 | $12,862 | 2023 |
| Endologix LLC | 7 | $9,425 | 2023 |
| ERBE USA Inc | 2 | $7,000 | 2023 |
| Impulse Dynamics (USA) Inc. | 2 | $4,822 | 2023 |
| Celgene Corporation | 1 | $3,000 | 2023 |
| Genetesis, Inc. | 4 | $2,400 | 2023 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,000 | 2023 |
| ABBVIE INC. | 1 | $2,000 | 2023 |
| Wilson Cook Medical Incorporated | 1 | $2,000 | 2023 |
| Pharmacyclics LLC, an AbbVie Company | 4 | $632 | 2023 |
| Biogen, Inc. | 1 | $380 | 2023 |
| Abbott Laboratories | 1 | $50 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 217 | $1,036,958 |
| Long term medical supply or device loan | 1 | $13,000 |
| Space rental or facility fees (teaching hospital only) | 4 | $8,000 |
| Honoraria | 1 | $5,000 |
| Education | 2 | $4,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2023 | |
| 2023-12-29 | PFIZER INC. | $7,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-12-29 | Penumbra, Inc. | $3,737 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-12-27 | Endologix LLC | $1,950 | Research payment | Cash or cash equivalent | ENDOCROSS Device Device, Cardiology/Vascular Diseases | Detour II Study | 2023 |
| 2023-12-22 | PFIZER INC. | $8,141 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-12-22 | PFIZER INC. | $4,440 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-12-14 | PFIZER INC. | $19,108 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-12-08 | PFIZER INC. | $13,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-12-07 | PFIZER INC. | $20,298 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-12-07 | PFIZER INC. | $8,195 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-12-04 | InspireMD Ltd | $16,716 | Research payment | Cash or cash equivalent | CGuard Device, Cardiology | Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting | 2023 |
| 2023-11-29 | Endologix LLC | $1,105 | Research payment | Cash or cash equivalent | Nellix 3.5 Confirm Study | 2023 | |
| 2023-11-25 | PFIZER INC. | $28,959 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-11-25 | PFIZER INC. | $8,255 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-11-21 | Medtronic, Inc. | $1,250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-11-21 | Medtronic, Inc. | $1,250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-11-21 | Medtronic, Inc. | $1,200 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-11-21 | Medtronic, Inc. | $1,200 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-11-20 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-11-20 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-11-20 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-11-20 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-11-15 | Medtronic, Inc. | $11,081 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-11-15 | Penumbra, Inc. | $2,948 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-11-09 | Impulse Dynamics (USA) Inc. | $3,822 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-11-04 | PFIZER INC. | $25,722 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-11-04 | PFIZER INC. | $1,919 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-11-03 | Saranas, Inc. | $1,750 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-10-27 | Saranas, Inc. | $2,500 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-10-27 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-10-26 | Medtronic, Inc. | $1,375 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-10-26 | Medtronic, Inc. | $1,375 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-10-26 | Medtronic, Inc. | $735 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-10-26 | Medtronic, Inc. | $735 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-10-26 | Medtronic, Inc. | $7 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2023 |
| 2023-10-25 | PFIZER INC. | $8,000 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-10-24 | PFIZER INC. | $3,456 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-10-23 | Penumbra, Inc. | $3,500 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-10-18 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2023 |
| 2023-10-18 | Medtronic, Inc. | $875 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2023 |
| 2023-10-18 | PFIZER INC. | $700 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-10-18 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2023 |
| 2023-10-18 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2023 |
| 2023-10-16 | Medtronic, Inc. | $1,960 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2023 |
| 2023-10-16 | Medtronic, Inc. | $1,960 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2023 |
| 2023-10-13 | Penumbra, Inc. | $848 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-10-11 | PFIZER INC. | $6,234 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-10-11 | PFIZER INC. | $3,023 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-10-03 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-09-23 | PFIZER INC. | $53,806 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-09-23 | PFIZER INC. | $543 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-09-20 | Eli Lilly and Company | $4,000 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIEN | 2023 | |
| 2023-09-19 | Penumbra, Inc. | $1,869 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-09-18 | Saranas, Inc. | $3,250 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-09-12 | Medtronic, Inc. | $1,968 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-09-12 | Medtronic, Inc. | $1,968 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-09-06 | Saranas, Inc. | $2,000 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-09-06 | Endologix LLC | $1,950 | Research payment | Cash or cash equivalent | ENDOCROSS Device Device, Cardiology/Vascular Diseases | Detour II Study | 2023 |
| 2023-09-06 | Impulse Dynamics (USA) Inc. | $1,000 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2023 |
| 2023-09-05 | Genetesis, Inc. | $1,750 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MICRO | 2023 |
| 2023-09-02 | PFIZER INC. | $35,013 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-09-02 | PFIZER INC. | $1,919 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-08-31 | Medtronic, Inc. | $5 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2023 |
| 2023-08-24 | PFIZER INC. | $25,949 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-08-24 | PFIZER INC. | $3,295 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-08-23 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-08-23 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-08-18 | Saranas, Inc. | $2,208 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-08-18 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-08-18 | Saranas, Inc. | $525 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-08-17 | PFIZER INC. | $154 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-08-15 | Medtronic, Inc. | $1,728 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-08-15 | Medtronic, Inc. | $1,728 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-08-15 | Penumbra, Inc. | $1,551 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-08-14 | Medtronic, Inc. | $1,375 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-08-14 | Medtronic, Inc. | $1,375 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-08-09 | Eli Lilly and Company | $33,065 | Research payment | Cash or cash equivalent | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE | 2023 | |
| 2023-08-08 | PFIZER INC. | $18,881 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-08-08 | PFIZER INC. | $3,023 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-08-03 | Penumbra, Inc. | $2,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-08-02 | Genentech, Inc. | $1,895 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-26 | PFIZER INC. | $46,618 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-07-26 | PFIZER INC. | $6,725 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-07-26 | PFIZER INC. | $703 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-07-19 | Gilead Sciences, Inc. | $1,040 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2023 |
| 2023-07-18 | Penumbra, Inc. | $138 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-07-13 | PFIZER INC. | $5,143 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-07-13 | Medtronic, Inc. | $400 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2023 |
| 2023-07-13 | Medtronic, Inc. | $400 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2023 |
| 2023-07-11 | PFIZER INC. | $13,336 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-07-11 | PFIZER INC. | $3,295 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-07-06 | PFIZER INC. | $10,146 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-07-06 | PFIZER INC. | $1,040 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-07-06 | Medtronic, Inc. | $228 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-07-06 | Medtronic, Inc. | $228 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-06-29 | PFIZER INC. | $2,213 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-28 | Genentech, Inc. | $7,353 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-06-28 | PFIZER INC. | $6,303 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-06-26 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | Tenecteplase in stroke patients between 4 5 and 24 hours | 2023 |
| 2023-06-26 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | Tenecteplase in stroke patients between 4 5 and 24 hours | 2023 |
| 2023-06-26 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | Tenecteplase in stroke patients between 4 5 and 24 hours | 2023 |
| 2023-06-26 | Genentech, Inc. | $40 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | Tenecteplase in stroke patients between 4 5 and 24 hours | 2023 |
| 2023-06-24 | PFIZER INC. | $3,966 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-06-24 | PFIZER INC. | $3,667 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-06-22 | PFIZER INC. | $463 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-21 | Gilead Sciences, Inc. | $833 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2023 |
| 2023-06-21 | Medtronic, Inc. | $55 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-06-21 | Medtronic, Inc. | $55 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-06-16 | PFIZER INC. | $27,693 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-16 | Genentech, Inc. | $3,924 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-06-14 | PFIZER INC. | $772 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-08 | PFIZER INC. | $25,215 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-06-08 | Penumbra, Inc. | $248 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-06-03 | PFIZER INC. | $3,091 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-03 | PFIZER INC. | $271 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-06-01 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2023 |
| 2023-06-01 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2023 |
| 2023-06-01 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2023 |
| 2023-06-01 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2023 |
| 2023-05-31 | Genetesis, Inc. | $250 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MICRO | 2023 |
| 2023-05-26 | PFIZER INC. | $18,911 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-05-25 | PFIZER INC. | $25,835 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-25 | PFIZER INC. | $2,851 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-05-25 | Saranas, Inc. | $2,308 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-05-25 | Saranas, Inc. | $150 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-05-16 | PFIZER INC. | $4,719 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-15 | Penumbra, Inc. | $801 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-05-12 | Medtronic, Inc. | $2,253 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-05-12 | Medtronic, Inc. | $2,253 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-05-12 | Medtronic, Inc. | $1,448 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-05-12 | Medtronic, Inc. | $1,448 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-05-11 | Medtronic, Inc. | $6,250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-05-11 | Medtronic, Inc. | $6,250 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-05-10 | Genentech, Inc. | $2,819 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-05-10 | PFIZER INC. | $1,854 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-10 | Genentech, Inc. | $1,293 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-05-10 | Abbott Laboratories | $50 | Research payment | Cash or cash equivalent | AVEIR Device, Cardiac Rhythm Management | The LEADLESS II IDE Study for the Nanostim Leadless Pacemaker | 2023 |
| 2023-05-09 | PFIZER INC. | $2,936 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-09 | Medtronic, Inc. | $423 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2023 |
| 2023-05-06 | PFIZER INC. | $2,751 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-05-03 | Celgene Corporation | $3,000 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A | 2023 |
| 2023-05-03 | Saranas, Inc. | $1,300 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-05-03 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-05-03 | Saranas, Inc. | $1,035 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-05-03 | Saranas, Inc. | $750 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-05-03 | Saranas, Inc. | $100 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-04-29 | ERBE USA Inc | $5,000 | Honoraria | Cash or cash equivalent | 2023 | ||
| 2023-04-27 | PFIZER INC. | $18,236 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-04-27 | Medtronic, Inc. | $6,858 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-04-27 | Medtronic, Inc. | $6,858 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-04-27 | Saranas, Inc. | $3,708 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-04-24 | Medtronic, Inc. | $2,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-04-24 | Medtronic, Inc. | $2,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2023 |
| 2023-04-24 | Genetesis, Inc. | $325 | Research payment | Cash or cash equivalent | CardioFlux Device, Cardiovascular Diagnostic | MICRO | 2023 |
| 2023-04-22 | PFIZER INC. | $12,500 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2023 | |
| 2023-04-21 | PFIZER INC. | $38,764 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-04-20 | Penumbra, Inc. | $945 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2023 |
| 2023-04-19 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-04-19 | Gilead Sciences, Inc. | $833 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2023 |
| 2023-04-13 | Medtronic, Inc. | $1,507 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2023 |
| 2023-04-13 | Medtronic, Inc. | $1,507 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2023 |
| 2023-04-12 | PFIZER INC. | $6,000 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-04-12 | PFIZER INC. | $2,510 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-04-09 | ERBE USA Inc | $2,000 | Education | Cash or cash equivalent | 2023 | ||
| 2023-04-07 | Genentech, Inc. | $4,242 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-04-07 | Genentech, Inc. | $2,819 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-04-07 | Genentech, Inc. | $1,769 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-30 | Endologix LLC | $1,105 | Research payment | Cash or cash equivalent | Nellix 3.5 Confirm Study | 2023 | |
| 2023-03-30 | Endologix LLC | $1,105 | Research payment | Cash or cash equivalent | Nellix 3.5 Confirm Study | 2023 | |
| 2023-03-30 | Endologix LLC | $1,105 | Research payment | Cash or cash equivalent | Nellix 3.5 Confirm Study | 2023 | |
| 2023-03-30 | Endologix LLC | $1,105 | Research payment | Cash or cash equivalent | Nellix 3.5 Confirm Study | 2023 | |
| 2023-03-29 | Gilead Sciences, Inc. | $3,840 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2023 |
| 2023-03-29 | Genentech, Inc. | $2,040 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-29 | Genentech, Inc. | $1,769 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-24 | PFIZER INC. | $1,268 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-03-23 | PFIZER INC. | $2,210 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-03-21 | Gilead Sciences, Inc. | $2,593 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2023 |
| 2023-03-18 | PFIZER INC. | $154 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-03-15 | Genentech, Inc. | $4,242 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-09 | PFIZER INC. | $13,788 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-03-09 | Saranas, Inc. | $2,000 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2023 | |
| 2023-03-07 | PFIZER INC. | $24,381 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-03-01 | PFIZER INC. | $4,329 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-03-01 | Gilead Sciences, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-02-28 | PFIZER INC. | $9,582 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-02-24 | Amgen Inc. | $14,000 | Research payment | Cash or cash equivalent | P0 ASCVD Olpasiran Prescreening for CVOT | 2023 | |
| 2023-02-22 | Gilead Sciences, Inc. | $683 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2023 |
| 2023-02-21 | Penumbra, Inc. | $2,000 | Education | Cash or cash equivalent | 2023 | ||
| 2023-02-21 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-02-21 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-02-21 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-02-21 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-02-21 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-02-21 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-02-18 | PFIZER INC. | $3,372 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-02-16 | Medtronic, Inc. | $300 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-02-16 | Medtronic, Inc. | $300 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-02-15 | PFIZER INC. | $2,144 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-02-11 | Medtronic, Inc. | $1,395 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2023 |
| 2023-02-10 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LINZESS Drug, GASTROENTEROLOGY | 2023 |
The latest 200 records of 225.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments